Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Blood Pressure Patterns and Hepatosteatosis: Cardiometabolic Risk Assessment in Dipper and Non-Dipper Phenotypes.

Autor: Astan, Ramazan¹ (AUTHOR) ramazan.astan@saglik.gov.tr, Patoulias, Dimitrios^2,3 (AUTHOR) dipatoulias@gmail.com, Ninić, Ana⁴ (AUTHOR) aninic@pharmacy.bg.ac.rs, Dayanan, Ramazan⁵ (AUTHOR) ramazan.dayanan@saglik.gov.tr, Karakasis, Paschalis⁶ (AUTHOR) pakar15@hotmail.com, Mercantepe, Tolga⁷ (AUTHOR) tolga.mercantepe@erdogan.edu.tr, Mercantepe, Filiz⁸ (AUTHOR) tolga.mercantepe@erdogan.edu.tr, Klisic, Aleksandra^9,10 (AUTHOR) aleksandranklisic@gmail.com

Publikováno v: Journal of Clinical Medicine. Nov2024, Vol. 13 Issue 22, p6976. 20p.

代谢相关脂肪性肝病的无创诊断与药物治疗.

Autor: 孙丹倪¹ sdn132529@163.com, 黄 勇¹, 张嘉宝¹, 王培¹ pwang@smmu.edu.cn

Publikováno v: Journal of Pharmaceutical Practice & Service. Oct2024, Vol. 42 Issue 10, p411-418. 8p.

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.

Autor: Iyer JS; PathAI, Boston, MA, USA.; Absci, Vancouver, WA, USA., Juyal D; PathAI, Boston, MA, USA., Le Q; PathAI, Boston, MA, USA., Shanis Z; PathAI, Boston, MA, USA., Pokkalla H; PathAI, Boston, MA, USA., Pouryahya M; PathAI, Boston, MA, USA.; AstraZeneca, Gaithersburg, MD, USA., Pedawi A; PathAI, Boston, MA, USA.; Atomwise, San Francisco, CA, USA., Stanford-Moore SA; PathAI, Boston, MA, USA., Biddle-Snead C; PathAI, Boston, MA, USA., Carrasco-Zevallos O; PathAI, Boston, MA, USA.; Johnson & Johnson, New Brunswick, NJ, USA., Lin M; PathAI, Boston, MA, USA.; Supernus Pharmaceuticals, Rockville, MD, USA., Egger R; PathAI, Boston, MA, USA., Hoffman S; PathAI, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Elliott H; PathAI, Boston, MA, USA.; BigHat Biosciences, San Mateo, CA, USA., Leidal K; PathAI, Boston, MA, USA.; Genesis Therapeutics, Burlingame, CA, USA., Myers RP; Gilead Sciences, Inc., Foster City, CA, USA.; OrsoBio, Inc., Palo Alto, CA, USA., Chung C; Gilead Sciences, Inc., Foster City, CA, USA.; Inipharm, San Diego, CA, USA., Billin AN; Gilead Sciences, Inc., Foster City, CA, USA., Watkins TR; Gilead Sciences, Inc., Foster City, CA, USA., Patterson SD; Gilead Sciences, Inc., Foster City, CA, USA., Resnick M; PathAI, Boston, MA, USA.; Rhode Island Hospital and The Miriam Hospital, Providence, RI, USA., Wack K; PathAI, Boston, MA, USA., Glickman J; PathAI, Boston, MA, USA.; Massachusetts General Hospital, Boston, MA, USA., Burt AD; NIHRB Medical Research Center, Newcastle University, Newcastle, UK., Loomba R; NAFLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, San Diego, CA, USA., Sanyal AJ; Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, VCU School of Medicine, Richmond, VA, USA., Glass B; PathAI, Boston, MA, USA., Montalto MC; PathAI, Boston, MA, USA.; Amgen, Thousand Oaks, CA, USA., Taylor-Weiner A; PathAI, Boston, MA, USA.; Absci, Vancouver, WA, USA., Wapinski I; PathAI, Boston, MA, USA.; Sanofi Pharmaceuticals, Cambridge, MA, USA., Beck AH; PathAI, Boston, MA, USA. andy.beck@pathai.com.

Publikováno v: Nature medicine [Nat Med] 2024 Oct; Vol. 30 (10), pp. 2914-2923. Date of Electronic Publication: 2024 Aug 07.

Polyphenols improve non‐alcoholic fatty liver disease via gut microbiota: A comprehensive review.

Autor: Mohammadhasani, Kimia¹ (AUTHOR), Vahedi Fard, Mohammad¹ (AUTHOR), Mottaghi Moghaddam Shahri, Ali² (AUTHOR) mottaghimsa@gmail.com, Khorasanchi, Zahra³ (AUTHOR) z.khorasanchi@gmail.com

Publikováno v: Food Science & Nutrition. Aug2024, Vol. 12 Issue 8, p5341-5356. 16p.